Bolt Biotherapeutics, Inc.
Developing immunotherapies that use antibody conjugates to help the immune system destroy cancer.
BOLT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0977021049
- LEI:
- Country:
- United States of America
- Address:
- 900 CHESAPEAKE DRIVE, 94063 REDWOOD CITY
- Website:
- https://boltbio.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company's approach leverages the body's innate and adaptive immune systems, utilizing myeloid cells to help recognize and destroy tumor cells. Its core technology is the proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which generates a pipeline of product candidates by combining tumor-targeting antibodies with expertise in myeloid biology. A lead candidate, BDC-3042, is a first-in-class Dectin-2 agonist antibody designed to repolarize immune cells from a tumor-supportive to a tumor-destructive state, and is currently under evaluation in clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Bolt Biotherapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bolt Biotherapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bolt Biotherapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
